Global Melanoma Drugs and Companies Pipeline Review H1 2017
Summary
The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/590075-melanoma-pipeline-review-h1-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Melanoma
- The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Melanoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content: Key Points
Table of Contents 2
Introduction 12
Melanoma Overview 13
Therapeutics Development 14
Melanoma - Therapeutics under Development by Companies 16
Melanoma - Therapeutics under Investigation by Universities/Institutes 37
Melanoma - Pipeline Products Glance 41
Melanoma - Products under Development by Companies 45
Melanoma - Products under Investigation by Universities/Institutes 73
Melanoma - Companies Involved in Therapeutics Development 79
Melanoma - Therapeutics Assessment 318
Drug Profiles 395
Melanoma - Dormant Projects 1366
Melanoma - Discontinued Products 1407
Melanoma - Product Development Milestones 1412
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/590075-melanoma-pipeline-review-h1-2016
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Posted by
Vivian Dsena
on Monday February 27 2017, 8:00 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
